Library

feed icon rss

Your email was sent successfully. Check your inbox.

An error occurred while sending the email. Please try again.

Proceed reservation?

Export
Filter
  • Key words Breast cancer  (1)
  • cell proliferation  (1)
  • megestrol acetate  (1)
  • 1
    ISSN: 1432-0843
    Keywords: Key words Breast cancer ; LH-RH analogues ; Leuprolide acetate
    Source: Springer Online Journal Archives 1860-2000
    Topics: Medicine
    Notes: Abstract Purpose: To evaluate the endocrinological and clinical activity of a new slow-release formulation of leuprolide acetate in breast cancer patients. Methods: A total of 50 pre- or perimenopausal patients with early- or late-stage breast cancer who were candidates for endocrine treatment were included in the study and randomly allocated to receive either 3.75 mg of leuprolide acetate every month or 11.25 mg of leuprolide acetate every 3 months. Patients were treated until disease recurrence or progression or for a maximum of 24 months. Treatment outcome, side effects, and serum levels of gonadotrophins, estradiol, progesterone, and Δ4-androstenedione were analyzed at different time points. Results: In all, 23 patients were allocated to the monthly formulation and 27, to the 3-monthly formulation. The median time on treatment was comparable. There was no evidence of any difference in clinical outcome or drug-induced side effects, hot flushes being recorded in about 50% of patients in both groups. Altogether, 35 patients were actively menstruating at the beginning of treatment; all of them became amenorrhoic after 3 months and remained so until treatment with leuprolide was continued, irrespective of the allocated treatment. All endocrine parameters, particularly estradiol levels, were suppressed to a similar extent. Conclusions: The present results indicate that the two formulations exert a comparable estrogen-suppressive effect and warrant further study of the 3-monthly formulation of leuprolide acetate in breast cancer patients.
    Type of Medium: Electronic Resource
    Library Location Call Number Volume/Issue/Year Availability
    BibTip Others were also interested in ...
  • 2
    Electronic Resource
    Electronic Resource
    Springer
    Breast cancer research and treatment 3 (1983), S. 23-32 
    ISSN: 1573-7217
    Keywords: cell proliferation ; culture contamination ; estrogen-sensitive cell lines ; steroid receptors
    Source: Springer Online Journal Archives 1860-2000
    Topics: Medicine
    Notes: Summary Two new estrogen-sensitive variants of MCF-7 human breast cancer cells, CG-4 and CG-5, are described in this report. These cells were derived from a casual contamination by MCF-7 cells of primary cultures from a human adenocarcinoma of the breast and a pleural effusion of a patient with advanced breast cancer, respectively. Careful characterization of these variants revealed chromosomal properties highly similar to and alloenzyme phenotypes identical to those of MCF-7 cells which were simultaneously cultured in the laboratory. MCF-7, CG-4 and CG-5 cells were tested for estrogen responsiveness under identical growth conditions, that is in the presence of culture medium supplemented with 5% charcoal-treated serum. While the number of MCF-7 cells increases by about 40% over the controls in the presence of physiological concentrations of estradiol, the number of CG-4 cells doubles and the number of CG-5 cells triples. All these cell lines have approximately the same number of estrogen, androgen, glucocorticoid, and progesterone receptor sites/cell. Since several difficulties arise in demonstrating the estrogen responsive growth stimulation of currently available human breast cancer cells, these two new variants, characterized by a high and reproducible estrogen responsiveness, afford a new model for studying the mechanisms by which estrogen regulates cell proliferation. The problems related to the careful characterization of every established cell line are discussed.
    Type of Medium: Electronic Resource
    Library Location Call Number Volume/Issue/Year Availability
    BibTip Others were also interested in ...
  • 3
    ISSN: 1573-7217
    Keywords: advanced breast cancer ; endocrine therapy ; megestrol acetate ; alpha 2a interferon
    Source: Springer Online Journal Archives 1860-2000
    Topics: Medicine
    Notes: Summary This phase II study was aimed to evaluate the activity of a combination of megestrol acetate (MA) and alpha 2a interferon (IFN) in a group of tamoxifen-responsive breast cancer patients. Thirty patients with metastatic breast cancer either previously treated with adjuvant tamoxifen for at least 24 months or treated with tamoxifen for metastatic disease and showing an objective response or stability of disease, were given MA (single daily dose of 160 mg per os) and alpha 2a IFN (3 million units - MU - three times per week intramuscularly -i.m. -). Of the 29 evaluable patients, 2 (6.8%) achieved a complete response and 4 (13.8%) a partial response for an overall response rate of 20.6% (95% confidence limits = 5.9%-35.4%). Treatment toxicity was mild and no patient had to discontinue or delay the treatment due to IFN side effects. Our results seem to rule out that alpha 2a IFN is able to improve the activity of MA as second-line therapy in tamoxifen-responsive patients.
    Type of Medium: Electronic Resource
    Library Location Call Number Volume/Issue/Year Availability
    BibTip Others were also interested in ...
Close ⊗
This website uses cookies and the analysis tool Matomo. More information can be found here...